Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2014

Open Access 01-12-2014 | Research article

Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis

Authors: Julia C Cutts, Rosanna Powell, Paul A Agius, James G Beeson, Julie A Simpson, Freya J I Fowkes

Published in: BMC Medicine | Issue 1/2014

Login to get access

Abstract

Background

Identifying Plasmodium vivax antigen-specific antibodies associated with P. vivax infection and protective immunity is key to the development of serosurveillance tools and vaccines for malaria. Antibody targets of P. vivax can be identified by seroepidemiological studies of individuals living in P. vivax-endemic areas, and is an important strategy given the limited ability to culture P. vivax in vitro. There have been numerous studies investigating the association between P. vivax antibody responses and P. vivax infection, but there has been no standardization of results to enable comparisons across populations.

Methods

We performed a systematic review with meta-analysis of population-based, cross-sectional, case-control, and cohort studies of individuals living in P. vivax-endemic areas. We searched 6 databases and identified 18 studies that met predefined inclusion and quality criteria, and examined the association between antibody responses to P. vivax antigens and P. vivax malaria.

Results

The majority of studies were published in South America (all from Brazil) and the rest from geographically diverse areas in the Asia-Pacific region. Considerable heterogeneity in estimates was observed, but IgG responses to PvCSP, PvMSP-119, PvMSP-9RIRII, and PvAMA1 were associated with increased odds of P. vivax infection in geographically diverse populations. Potential sources of heterogeneity included study design, different transmission intensities and transmigrant populations. Protective associations were observed for antibodies to PvMSP-119, PvMSP-1NT, PvMSP-3α and PvMSP-9NT antigens, but only in single geographical locations.

Conclusions

This systematic review revealed several antigen-specific antibodies that were associated with active infection and protective immunity, which may be useful biomarkers. However, more studies are needed on additional antigens, particularly cohort studies to increase the body of evidence for protective immunity. More studies representing diverse geographical regions encompassing varying P. vivax endemicities are needed to validate the generalizability of the findings and to provide a solid evidence base for the use of P. vivax antigens in vaccines and serosurveillance tools.
Appendix
Available only for authorised users
Literature
1.
Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI: The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010, 4: e774-10.1371/journal.pntd.0000774.CrossRefPubMedPubMedCentral
2.
Anstey NM, Douglas NM, Poespoprodjo JR, Price RN: Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol. 2012, 80: 151-201. 10.1016/B978-0-12-397900-1.00003-7.CrossRefPubMed
3.
A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med. 2011, 8: e1000396-10.1371/journal.pmed.1000396.
4.
A research agenda for malaria eradication: vaccines. PLoS Med. 2011, 8: e1000398-10.1371/journal.pmed.1000398.
5.
6.
Herrera S, Fernandez OL, Vera O, Cardenas W, Ramirez O, Palacios R, Chen-Mok M, Corradin G, Arevalo-Herrera M: Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg. 2011, 84: 12-20. 10.4269/ajtmh.2011.09-0516.CrossRefPubMedPubMedCentral
7.
Richards JS, Beeson JG: The future for blood-stage vaccines against malaria. Immunol Cell Biol. 2009, 87: 377-390. 10.1038/icb.2009.27.CrossRefPubMed
8.
Mueller I, Galinski MR, Tsuboi T, Arevalo-Herrera M, Collins WE, King CL: Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. Adv Parasitol. 2013, 81: 77-131. 10.1016/B978-0-12-407826-0.00003-5.CrossRefPubMed
9.
Marsh K, Kinyanjui S: Immune effector mechanisms in malaria. Parasite Immunol. 2006, 28: 51-60. 10.1111/j.1365-3024.2006.00808.x.CrossRefPubMed
10.
11.
Fowkes FJ, Richards JS, Simpson JA, Beeson JG: The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 2010, 7: e1000218-10.1371/journal.pmed.1000218.CrossRefPubMedPubMedCentral
12.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283: 2008-2012. 10.1001/jama.283.15.2008.CrossRefPubMed
13.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6: e1000097-10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral
14.
Zhang J, Yu KF: What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998, 280: 1690-1691. 10.1001/jama.280.19.1690.CrossRefPubMed
15.
The RTS: S Clinical Trials Partnership: First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med. 2011, 365: 1863-1875. 10.1056/NEJMoa1102287.CrossRef
16.
The RTS: S Clinical Trials Partnership: A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med. 2012, 367: 2284-2295. 10.1056/NEJMoa1208394.CrossRef
17.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
18.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. Br Med J. 2003, 327: 557-560. 10.1136/bmj.327.7414.557.CrossRef
19.
Ioannidis JP: Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008, 14: 951-957. 10.1111/j.1365-2753.2008.00986.x.CrossRefPubMed
20.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21: 1539-1558. 10.1002/sim.1186.CrossRefPubMed
21.
Deeks JJ HJ, Altman DG: Chapter 9: Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Edited by Higgins JPT, Green S. The Cochrane Collaboration; 2011. Available from ., [www.​cochrane-handbook.​org]
22.
Fernandez-Becerra C, Sanz S, Brucet M, Stanisic DI, Alves FP, Camargo EP, Alonso PL, Mueller I, del Portillo HA: Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. Malar J. 2010, 9: 29-10.1186/1475-2875-9-29.CrossRefPubMedPubMedCentral
23.
Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, Nogueira PA, Goncalves AQ, Fontes CJ, Soares IS, Brito CF, Rocha RS, Carvalho LH: Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon region. Trop Med Int Health. 2012, 17: 989-1000. 10.1111/j.1365-3156.2012.03016.x.CrossRefPubMed
24.
Lima-Junior JC, Tran TM, Meyer EV, Singh B, De-Simone SG, Santos F, Daniel-Ribeiro CT, Moreno A, Barnwell JW, Galinski MR, Oliveira-Ferreira J: Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine. 2008, 26: 6645-6654. 10.1016/j.vaccine.2008.09.029.CrossRefPubMedPubMedCentral
25.
Lima-Junior JC, Jiang J, Rodrigues-da-Silva RN, Banic DM, Tran TM, Ribeiro RY, Meyer VSE, De-Simone SG, Santos F, Moreno A, Barnwell JW, Galinski MR, Oliveira-Ferreira J: B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3 α) in malaria exposed individuals from Brazilian Amazon. Vaccine. 2011, 29: 1801-1811. 10.1016/j.vaccine.2010.12.099.CrossRefPubMedPubMedCentral
26.
Lima-Junior JC, Rodrigues-da-Silva RN, Banic DM, Jiang J, Singh B, Fabricio-Silva GM, Porto LC, Meyer EV, Moreno A, Rodrigues MM, Barnwell JW, Galinski MR, de Oliveira-Ferreira J: Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3alpha and MSP-9 in individuals from Brazilian endemic area. PLoS One. 2012, 7: e36419-10.1371/journal.pone.0036419.CrossRefPubMedPubMedCentral
27.
Nogueira PA, Alves FP, Fernandez-Becerra C, Pein O, Santos NR, da Silva LHP, Camargo EP, del Portillo HA: A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun. 2006, 74: 2726-2733. 10.1128/IAI.74.5.2726-2733.2006.CrossRefPubMedPubMedCentral
28.
Oliveira-Ferreira J, Pratt-Riccio LR, Arruda M, Santos F, Ribeiro CT, Goldberg AC, Banic DM: HLA class II and antibody responses to circumsporozoite protein repeats of P. vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malaria. Acta Trop. 2004, 92: 63-69. 10.1016/j.actatropica.2004.02.011.CrossRefPubMed
29.
Souza-Silva FA, Da Silva-Nunes M, Sanchez BAM, Ceravolo IP, Malafronte RS, Brito CFA, Ferreira MU, Carvalho LH: Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in rural Brazilian Amazon. Am J Trop Med Hyg. 2010, 82: 185-193. 10.4269/ajtmh.2010.08-0580.CrossRefPubMedPubMedCentral
30.
Tran TM, Oliveira-Ferreira J, Moreno A, Santos F, Yazdani SS, Chitnis CE, Altman JD, Meyer EV, Barnwell JW, Galinski MR: Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am J Trop Med Hyg. 2005, 73: 244-255.PubMed
31.
Versiani FG, Almeida ME, Melo GC, Versiani FO, Orlandi PP, Mariuba LA, Soares LA, Souza LP, da Silva Balieiro AA, Monteiro WM, Costa FT, del Portillo HA, Lacerda MV, Nogueira PA: High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms. Malar J. 2013, 12: 294-10.1186/1475-2875-12-294.CrossRefPubMedPubMedCentral
32.
Ak M, Jones TR, Charoenvit Y, Kumar S, Kaslow DC, Maris D, Marwoto H, Masbar S, Hoffman SL: Humoral immune responses against Plasmodium vivax MSP1 in humans living in a malaria endemic area in Flores, Indonesia. Southeast Asian J Trop Med Public Health. 1998, 29: 685-691.PubMed
33.
Woodberry T, Minigo G, Piera KA, Hanley JC, de Silva HD, Salwati E, Kenangalem E, Tjitra E, Coppel RL, Price RN, Anstey NM, Plebanski M: Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis. 2008, 198: 134-142. 10.1086/588711.CrossRefPubMed
34.
Cole-Tobian JL, Michon P, Biasor M, Richards JS, Beeson JG, Mueller I, King CL: Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect Immun. 2009, 77: 4009-4017. 10.1128/IAI.00158-09.CrossRefPubMedPubMedCentral
35.
King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE: Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A. 2008, 105: 8363-8368. 10.1073/pnas.0800371105.CrossRefPubMedPubMedCentral
36.
Stanisic DI, Javati S, Kiniboro B, Lin E, Jiang J, Singh B, Meyer EV, Siba P, Koepfli C, Felger I, Galinski MR, Mueller I: Naturally Acquired immune responses to P. vivax merozoite surface protein 3alpha and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children. PLoS Negl Trop Dis. 2013, 7: e2498-10.1371/journal.pntd.0002498.CrossRefPubMedPubMedCentral
37.
Fowkes FJ, McGready R, Cross NJ, Hommel M, Simpson JA, Elliott SR, Richards JS, Lackovic K, Viladpai-Nguen J, Narum D, Tsuboi T, Anders RF, Nosten F, Beeson JG: New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis. 2012, 206: 1612-1621. 10.1093/infdis/jis566.CrossRefPubMedPubMedCentral
38.
Wongsrichanalai C, Webster HK, Permpanich B, Chuanak N, Ketrangsri S: Naturally acquired circumsporozoite antibodies and their role in protection in endemic falciparum and vivax malaria. Am J Trop Med Hyg. 1991, 44: 201-204.PubMed
39.
Yildiz Zeyrek F, Palacpac N, Yuksel F, Yagi M, Honjo K, Fujita Y, Arisue N, Takeo S, Tanabe K, Horii T, Tsuboi T, Ishii KJ, Coban C: Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax. PLoS One. 2011, 6: e28126-10.1371/journal.pone.0028126.CrossRefPubMedPubMedCentral
40.
Yildiz Zeyrek F, Babaoglu A, Demirel S, Erdogan DD, Ak M, Korkmaz M, Coban C: Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa. Turkey Am J Trop Med Hyg. 2008, 78: 729-732.
41.
Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, Chomcharn Y: Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med. 1982, 156: 20-30. 10.1084/jem.156.1.20.CrossRefPubMed
42.
Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP, Prasittisuk C: Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science. 1989, 245: 973-976. 10.1126/science.2672336.CrossRefPubMed
43.
Qari SH, Shi Y-P, Goldman IF, Alpers MP, Collins WE, Lal AA: Identification of Plasmodium vivax-like human malaria parasite. Lancet. 1993, 341: 780-783. 10.1016/0140-6736(93)90559-Y.CrossRefPubMed
44.
45.
Chitnis CE, Chaudhuri A, Horuk R, Pogo AO, Miller LH: The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J Exp Med. 1996, 184: 1531-1536. 10.1084/jem.184.4.1531.CrossRefPubMed
46.
Ranjan A, Chitnis CE: Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc Natl Acad Sci U S A. 1999, 96: 14067-14072. 10.1073/pnas.96.24.14067.CrossRefPubMedPubMedCentral
47.
Fraser T, Michon P, Barnwell JW, Noe AR, Al-Yaman F, Kaslow DC, Adams JH: Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect Immun. 1997, 65: 2772-2777.PubMedPubMedCentral
48.
Tanabe K, Escalante A, Sakihama N, Honda M, Arisue N, Horii T, Culleton R, Hayakawa T, Hashimoto T, Longacre S, Pathirana S, Handunnetti S, Kishino H: Recent independent evolution of msp1 polymorphism in Plasmodium vivax and related simian malaria parasites. Mol Biochem Parasitol. 2007, 156: 74-79. 10.1016/j.molbiopara.2007.07.002.CrossRefPubMed
49.
Pasay MC, Cheng Q, Rzepczyk C, Saul A: Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1. Mol Biochem Parasitol. 1995, 70: 217-219. 10.1016/0166-6851(95)00015-S.CrossRefPubMed
50.
Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, Shai S: A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz. 1992, 87: 37-42. 10.1590/S0074-02761992000700004.CrossRefPubMed
51.
Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA: A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med. 1990, 172: 379-382. 10.1084/jem.172.1.379.CrossRefPubMed
52.
Blackman MJ, Ling IT, Nicholls SC, Holder AA: Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol. 1991, 49: 29-33. 10.1016/0166-6851(91)90127-R.CrossRefPubMed
53.
Galinski MR, Corredor-Medina C, Povoa M, Crosby J, Ingravallo P, Barnwell JW: Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domain. Mol Biochem Parasitol. 1999, 101: 131-147. 10.1016/S0166-6851(99)00063-8.CrossRefPubMed
54.
Rayner JC, Corredor V, Feldman D, Ingravallo P, Iderabdullah F, Galinski MR, Barnwell JW: Extensive polymorphism in the Plasmodium vivax merozoite surface coat protein MSP-3alpha is limited to specific domains. Parasitology. 2002, 125: 393-405. 10.1017/S0031182002002317.CrossRefPubMed
55.
Gomez A, Suarez CF, Martinez P, Saravia C, Patarroyo MA: High polymorphism in Plasmodium vivax merozoite surface protein-5 (MSP5). Parasitology. 2006, 133: 661-672. 10.1017/S0031182006001168.CrossRefPubMed
56.
Black CG, Barnwell JW, Huber CS, Galinski MR, Coppel RL: The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoite. Mol Biochem Parasitol. 2002, 120: 215-224. 10.1016/S0166-6851(01)00458-3.CrossRefPubMed
57.
Vargas-Serrato E, Barnwell JW, Ingravallo P, Perler FB, Galinski MR: Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum. Mol Biochem Parasitol. 2002, 120: 41-52. 10.1016/S0166-6851(01)00433-9.CrossRefPubMed
58.
Barnwell JW, Galinski MR, DeSimone SG, Perler F, Ingravallo P: Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites. Exp Parasitol. 1999, 91: 238-249. 10.1006/expr.1998.4372.CrossRefPubMed
59.
Galinski MR, Medina CC, Ingravallo P, Barnwell JW: A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell. 1992, 69: 1213-1226. 10.1016/0092-8674(92)90642-P.CrossRefPubMed
60.
Galinski MR, Xu M, Barnwell JW: Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) shares structural features with PvRBP-1 and the Plasmodium yoelii 235 kDa rhoptry protein family. Mol Biochem Parasitol. 2000, 108: 257-262. 10.1016/S0166-6851(00)00219-X.CrossRefPubMed
61.
Galinski MR, Barnwell JW: Plasmodium vivax: merozoites, invasion of reticulocytes and considerations for malaria vaccine development. Parasitology Today (Personal ed). 1996, 12: 20-29. 10.1016/0169-4758(96)80641-7.CrossRef
62.
Palacpac NM, Leung BW, Arisue N, Tanabe K, Sattabongkot J, Tsuboi T, Torii M, Udomsangpetch R, Horii T: Plasmodium vivax serine repeat antigen (SERA) multigene family exhibits similar expression patterns in independent infections. Mol Biochem Parasitol. 2006, 150: 353-358. 10.1016/j.molbiopara.2006.07.006.CrossRefPubMed
63.
Cho D, Kim KH, Park SC, Kim YK, Lee KN, Lim CS: Evaluation of rapid immunocapture assays for diagnosis of Plasmodium vivax in Korea. Parasitol Res. 2001, 87: 445-448. 10.1007/s004360000360.CrossRefPubMed
64.
Kim S, Ahn HJ, Kim TS, Nam HW: ELISA detection of vivax malaria with recombinant multiple stage-specific antigens and its application to survey of residents in endemic areas. Korean J Parasitol. 2003, 41: 203-207. 10.3347/kjp.2003.41.4.203.CrossRefPubMedPubMedCentral
65.
Lee KN, Suh IB, Chang EA, Kim SD, Cho NS, Park PW, An SS, Park O, Lim C: Prevalence of antibodies to the circumsporozite protein of Plasmodium vivax in five different regions of Korea. Trop Med Int Health. 2003, 8: 1062-1067. 10.1046/j.1360-2276.2003.01136.x.CrossRefPubMed
66.
Park SK, Lee KW, Hong SH, Kim DS, Lee JH, Jeon BH, Kim WS, Shin HJ, An SH, Park H: Development and evaluation of an immunochromatographic kit for the detection of antibody to Plasmodium vivax infection in South Korea. Yonsei Med J. 2003, 44: 747-750.CrossRefPubMed
67.
Suh IB, Lee KH, Kim YR, Woo SK, Kang HY, Won YD, An SS, Cho M, Cho D, Lim CS: Comparison of immunological responses to the various types circumsporozoite proteins of Plasmodium vivax in malaria patients of Korea. Microbiol Immunol. 2004, 48: 119-123. 10.1111/j.1348-0421.2004.tb03497.x.CrossRefPubMed
68.
Cook J, Reid H, Iavro J, Kuwahata M, Taleo G, Clements A, McCarthy J, Vallely A, Drakeley C: Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J. 2010, 9: 169-10.1186/1475-2875-9-169.CrossRefPubMedPubMedCentral
69.
Cook J, Speybroeck N, Sochanta T, Somony H, Sokny M, Claes F, Lemmens K, Theisen M, Soares IS, D’Alessandro U, Coosemans M, Erhart A: Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia. Malar J. 2012, 11: 86-10.1186/1475-2875-11-86.CrossRefPubMedPubMedCentral
70.
Bousema T, Youssef RM, Cook J, Cox J, Alegana VA, Amran J, Noor AM, Snow RW, Drakeley C: Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008. Emerg Infect Dis. 2010, 16: 392-399. 10.3201/eid1603.090732.CrossRefPubMedPubMedCentral
71.
Schwartz L, Brown GV, Genton B, Moorthy VS: A review of malaria vaccine clinical projects based on the WHO rainbow table. Malaria J. 2012, 11: 11-10.1186/1475-2875-11-11.CrossRef
72.
Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A: Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005, 23: 3131-3138. 10.1016/j.vaccine.2004.12.019.CrossRefPubMed
73.
Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP: Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One. 2008, 3: e2636-10.1371/journal.pone.0002636.CrossRefPubMedPubMedCentral
74.
Bredius RG, Fijen CA, De Haas M, Kuijper EJ, Weening RS, Van de Winkel JG, Out TA: Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. 1994, 83: 624-630.PubMedPubMedCentral
Metadata
Title
Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis
Authors
Julia C Cutts
Rosanna Powell
Paul A Agius
James G Beeson
Julie A Simpson
Freya J I Fowkes
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2014
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-014-0150-1

Other articles of this Issue 1/2014

BMC Medicine 1/2014 Go to the issue

Review

Predicting outcome from dengue

Research article

Inequalities in child mortality in ten major African cities

Research article

Burden of mental disorders and unmet needs among street homeless people in Addis Ababa, Ethiopia

Research article

Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts

Research article

Altered thyroid hormone profile in offspring after exposure to high estradiol environment during the first trimester of pregnancy: a cross-sectional study

Research article

The effects of antenatal dietary and lifestyle advice for women who are overweight or obese on neonatal health outcomes: the LIMIT randomised trial